For years, northern Cyprus, has marketed itself as a fertility tourism hotspot. Promising shorter waiting times, lower costs, and access to treatments restricted elsewhere, it has drawn thousands of hopeful parents from the UK and beyond.
But recent high-profile cases have cast a harsh light on the industry, raising questions about safety, ethics, and regulation. Beneath the glossy clinic websites and success stories lies a more complex and troubling reality.
In 2026, a major investigation revealed that several UK families who underwent IVF treatment in northern Cyprus may have been given the wrong sperm or egg donors. DNA testing suggested that at least seven children were conceived using genetic material different from what their parents had selected.
For affected families, the consequences have been profound. What was meant to be a carefully planned path to parenthood has instead resulted in confusion over identity, medical history, and trust.
While such mix-ups are considered extremely rare in tightly regulated systems, their occurrence here highlights a deeper issue – the absence of robust oversight.
The regulation gap
One of the most significant pitfalls of seeking fertility treatment in northern Cyprus is the lack of regulation.
Unlike the UK, which has a dedicated regulatory authority overseeing fertility clinics in the Human Fertilisation and Embryology Authority (HFEA), northern Cyprus lacks an equivalent independent body. This means:
- Fewer safeguards around donor tracking
- Limited accountability when things go wrong
- No clear pathway for complaints or compensation
Even when concerns are raised, investigations can be slow or opaque. Authorities have recently launched probes into clinics implicated in the donor mix-up cases, but outcomes remain uncertain.
The danger of “fertility tourism”
Northern Cyprus has become popular not just because of cost, but because it offers treatments that may be restricted or unavailable in the UK, such as:
- anonymous egg and sperm donation
- higher numbers of embryo transfers
- non-medical sex selection
This flexibility can feel empowering for those seeking treatment, but it often comes with trade-offs. Patients may assume that medical standards mirror those at home. In reality, legal frameworks and ethical guidelines can differ dramatically. As one investigation noted, the region’s popularity is partly driven by “lower costs and fewer restrictions,” but that same lack of restriction can increase risk.
Investigations into the wider fertility and surrogacy industry in northern Cyprus have highlighted issues such as:
- weak oversight of clinics and agencies
- potential exploitation of egg donors and surrogate mothers
- cross-border arrangements that exist in legal grey areas
Experts warn that inconsistent international regulations create opportunities for unethical practices, including coercion and poor informed consent.
In some cases, vulnerable women may be drawn into donation or surrogacy arrangements due to financial pressures, raising serious ethical questions about consent and exploitation.
One recently reported case involved an English same-sex couple, Laura and Beth, who underwent treatment at the Dogus IVF Centre in northern Cyprus. They had carefully planned their family, selecting a single donor so their children would be biologically related. However, years later, DNA tests revealed that the sperm donor was not the one they had chosen and further, their two children were conceived using different donors altogether, meaning the siblings were not biologically related to each other as intended. This revelation, which emerged nearly a decade after treatment, underscores one of the most unsettling risks of poorly regulated fertility care. Mistakes may not become apparent until years later, when the emotional, ethical, and identity implications are far more complex and difficult to resolve.
The emotional cost
Beyond legal and ethical concerns lies a deeply human impact. For families affected by donor mix-ups, the consequences are lifelong. There are children growing up without accurate genetic histories and parents facing difficult conversations about identity.
Even in successful cases, the lack of transparency can leave patients questioning what really happened during their treatment.
What prospective parents should consider
The northern Cyprus cases are not an argument against fertility treatment abroad, but they are a warning. Anyone considering treatment overseas should carefully evaluate:
- Regulation: Is there an independent authority overseeing clinics?
- Traceability: How are donors tracked and verified?
- Legal protections: What happens if something goes wrong?
- Transparency: Are procedures and risks clearly explained?
A turning point?
The recent revelations may mark a turning point for fertility tourism. As awareness grows, so too does pressure for greater international regulation and transparency. For now, the burden remains largely on patients to do their due diligence, often in unfamiliar legal and medical systems.
The promise of parenthood is powerful. But as the northern Cyprus cases show, when that promise is built on weak oversight, the consequences can be far-reaching, deeply personal, and impossible to undo.
Nichola Bright, Partner – Family Law
Myerson Limited
